Actuate Therapeutics
FORT WORTH, Texas, United States · Healthcare, Health Care
Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as c
Key facts
- Headquarters
- FORT WORTH, Texas, United States
- Employees
- 14
- Industries
- Healthcare, Health Care
- Status
- Public (ACTU)
- Website
- actuatetherapeutics.com
- Company page
Recent activity at Actuate Therapeutics
- : SEC 8-K (1.01): On October 26, 2026, Actuate Therapeutics, Inc. entered into an Underwriting Agreement with Newbridge Securities Corporation for the issuance and sale of 30,985,900 shares of common stock and warrants to purchase up to 15,492,950 shares of common stock, at a combined public offering price of $0.71 per set of two shares and one warrant. The Offering closed on October 28, 2026, and the Company received approximately $9.96 million in net proceeds. The Underwriting Agreement includes typical representations, warranties, and indemnifications, along with an over-allotment option for the Underwriter to purchase additional shares. The agreement, executed in compliance with FINRA regulations, features a 180-day lock-up for certain warrants granted to the Underwriter.
- : Actuate Therapeutics Raises $9.96 Million in Public Offering
- : SEC 8-K (7.01): On May 11, 2026, Actuate Therapeutics, Inc. announced that it received FDA clearance for its Investigational New Drug (IND) application to conduct a Phase 1/2 study for elraglusib. This significant regulatory milestone allows the company to further advance the development program for elraglusib, which may enhance its therapeutic offerings. The press release and corporate presentation detailing this development are included as exhibits 99.1 and 99.2, respectively. This FDA clearance is expected to positively impact the company’s strategy and future clinical development efforts.
- : SEC 8-K (5.02): On May 1, 2026, Actuate Therapeutics, Inc. appointed Dr. Martin H. Huber to fill a newly created seat on its Board of Directors, expanding the Board from seven to eight members. He will serve as a Class III director until the 2027 annual meeting of stockholders. Dr. Huber will receive compensation through an initial grant of 30,000 stock options, vesting over three years, and an annual retainer of $44,000. Additionally, a consulting agreement was signed with Dr. Huber for advisory services, providing a quarterly fee of $3,000. The Company announced this appointment in a press release on May 6, 2026, which aligns with the recent change in governance.
- : SEC 8-K (7.01): On January 12, 2026, Actuate Therapeutics, Inc. announced updated data from its fully enrolled Phase 2 trial for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). This disclosure falls under Regulation FD, indicating the company is providing important information to the public that may affect investor decisions. The update may have significant implications for the company's future strategies regarding treatment options in oncology, especially regarding funding and partnership opportunities arising from trial results. The full press release is provided as Exhibit 99.1 and is incorporated into this report.
- : SEC 8-K (1.01): On November 28, 2025, Actuate Therapeutics, Inc. entered into an At the Market Issuance Sales Agreement with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC. Under this agreement, the company may offer and sell shares of its common stock valued at up to $100,000,000 at its discretion. The sales will be made through the Sales Agents under the Company's effective Registration Statement on Form S-3 (File No. 333-289988), which was previously filed with the SEC on September 2, 2025. This strategic move allows the company to raise capital efficiently as it can adjust the timing and amount of shares sold based on market conditions.
- : SEC 8-K (1.01): On November 28, 2025, Actuate Therapeutics, Inc. entered into a Material Definitive Agreement titled 'At the Market Issuance Sales Agreement' with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC, allowing the Company to offer and sell up to $100,000,000 of its common stock. This agreement permits sales through the sales agents under the Company's effective Registration Statement on Form S-3. The Company will pay the Sales Agents a commission of up to 3.0% on the gross sales proceeds, along with customary indemnification rights. This arrangement allows Actuate to raise capital in a flexible manner as market conditions permit, which may have significant strategic implications for its future funding and operations.
- : SEC 8-K (8.01):
- : ACTUATE THERAPEUTICS
- : ACTUATE THERAPEUTICS
Actuate Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Post-IPO Equity | $10.0M |
| Jul 2025 | Seed | $4.7M |
| Mar 2024 | Seed | $3.0M |
| Oct 2022 | Venture | $11.2M |
| Dec 2020 | Venture | $14.5M |
Leadership
- Dan Schmitt, Executive Officer, Director
- NEIL BAJPAYEE, Director
- ALEX ANDRIANOPOULOS, Director
- LESLIE JR., Director
- AARON FLETCHER, Director
- Daniel Schmitt, Executive Officer, Director
Verified email and direct lines for Actuate Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Actuate Therapeutics in the news
- Actuate Therapeutics Announces Nature Medicine Publication - GlobeNewswire (Apr 14, 2026)
- Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer - Yahoo Finance (Jun 01, 2026)
- Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Nasdaq (Mar 24, 2026)
- Actuate Therapeutics Reports Synergistic Preclinical Activity of Elraglusib with RAS-Targeted Agents in Pancreatic Cancer Models - Quiver Quantitative (Sep 09, 2026)
- Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance (Sep 09, 2026)
- Actuate Therapeutics Announces FDA Clearance of IND for - GlobeNewswire (May 11, 2026)
- Actuate Therapeutics Reports Positive Follow-Up Data from - GlobeNewswire (Jan 12, 2026)
- Actuate Therapeutics, Inc. Common stock (ACTU) stock price, news, quote and history - Yahoo Finance Singapore (Jun 28, 2024)
Companies similar to Actuate Therapeutics
- Curadel Surgical Innovations · Healthcare, Health Care
- Galera Therapeutics · Healthcare, Health Care
- Akadeum Life Sciences · Healthcare, Health Care
- Resbiotic · Healthcare, Health Care
- Kernal Biologics · Healthcare, Health Care
About Actuate Therapeutics: questions and answers
What does Actuate Therapeutics do?
Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as c
Where is Actuate Therapeutics headquartered?
Actuate Therapeutics is headquartered in FORT WORTH, Texas, United States.
How many employees does Actuate Therapeutics have?
Actuate Therapeutics has about 14 employees.
Has Actuate Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for Actuate Therapeutics. The most recent, Post-IPO Equity of $10.0M, was in Oct 2026.
What is the latest news on Actuate Therapeutics?
On Oct 28, 2026, SEC 8-K (1.01): On October 26, 2026, Actuate Therapeutics, Inc. entered into an Underwriting Agreement with Newbridge Securities Corporation for the issuance and sale of 30,985,900 shares of common stock and warrants to purchase up to 15,492,950 shares of common stock, at a combined public offering
Is Actuate Therapeutics a public company?
Yes. Actuate Therapeutics is publicly traded under the ticker ACTU.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy